year 11, Issue 1 (March - April 2017)                   Iran J Med Microbiol 2017, 11(1): 9-17 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mahdavi M, Zahraei Salehi T, Amini K, Mobasseri P. Frequency of exoY, exoS, exoT and exoU genes among Pseudomonas aeruginosa Isolated from patients in Tehran hospitals by Multiplex PCR. Iran J Med Microbiol. 2017; 11 (1) :9-17
1- Department of Microbiology, Faculty of Basic Science, Saveh Branch, Islamic Azad University, Saveh, Iran
2- Department of Microbiology, Faculty of Veterinary medicine, Tehran University, Tehran, Iran ,
3- Department of Microbiology, Faculty of Biology sciences, Tehran North Branch, Islamic Azad University, Tehran, Iran
Abstract:   (7398 Views)

Background and Aim: Pseudomonas aeruginosa is a gram-negative pathogen that causes a variety of serious infections predominantly in immunocompromised patients. To promote severe illness, P. aeruginosa uses a type III secretion system to inject toxic effector proteins into the cytoplasm of eukaryotic cells. Four effector proteins have been described in P. aeruginosa: ExoU, ExoS, ExoT, and ExoY. The aim of the study was to determine the prevalence of the type III secretion system toxins-encoding genes among P. aeruginosa isolates collected from different clinical specimens such as urine, wound, blood and respiratory secretions from patients.

Materials and Methods: 55 Pseudomonas aeruginosa isolates were identified from hospitalized patients in Tehran during 2015 – 2016, using conventional microbiological tests. The susceptibility of isolates to antibiotics were assessed using disk diffusion test. After DNA extraction, Multiplex PCR was performed on the P. aeruginosa isolates to detect the secretion toxins-encoding genes.

Results: High resistance rates were seen for cefipime (89%), ceftazidime (85.45%), aztreonam (83.63%), tobramycin (78.18%) and gentamicin (60%). The prevalence of the genes among all isolates was as follows; exoT (76.32%), exoS (30.90%), exoY (14.54%) and exoU (67.27%). exoU was more prevalent among MDR than in non-MDR strains (81.3% versus16.6%). exoU+ isolates were more likely to be fluoroquinolone-resistant than exoS+ isolates (32% versus 17%).

Conclusions: Type III secretion system toxins-encoding genes found in isolated P.aeruginosa, in which exoT, exoU and exoS gene detected in most isolates while exoY gene was detected in minaroty of the isolates.

Full-Text [PDF 871 kb]   (1896 Downloads)    
Type of Study: Original | Subject: Molecular Microbiology
Received: 2016/04/17 | Accepted: 2016/07/24 | ePublished: 2016/10/17

1. Papagheorghe R. Bloodstream infections in immunocompromised hosts. Roum Arch Microbiol Immunol 2012; 71(2):87-94. [PubMed]
2. Samonis G, Vardakas KZ, Maraki S, Tansarli GS, Dimopoulou D, Kofteridis DP, et al. A prospective study of characteristics and outcomes of bacteremia in patients with solid organ or hematologic malignancies. Support Care Cancer 2013; 21(9): 2521-6. [PubMed]
3. Bassetti M, Righi E, Viscoli C. Pseudomonas aeruginosa serious infections: mono or combination antimicrobial therapy? Curr Med Chem 2008; 15(5): 517-22. [PubMed]
4. Van Delden C. Pseudomonas aeruginosa bloodstream infections: how should we treat them? Int J Antimicrob Agents 2007; 30(1):71–75. [PubMed]
5. Anderson ET, Young LS, Hewitt WL: Antimicrobial synergism in the therapy of gram-negative rod bacteremia. Chemotherapy 1978; 24(1): 45-54. [PubMed]
6. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 2004; 328(7441): 668. [PubMed]
7. Ra'oof WM. Distribution of algD, lasB, pilB and nan1 genes among MDR clinical isolates of Pseudomonas aeruginosa in respect to the site of infection. Tikrit Med J 2011; 17(2): 148-60. [Article]
8. Rashno Taee S, Khansarinejad B, Abtahi H, Najafimosleh M, Ghaznavi-Rad E. Detection of algD, oprL and exoA Genes by New Specific Primers as an Efficient, Rapid and Accurate Procedure for Direct Diagnosis of Pseudomonas aeruginosa Strains in Clinical Samples. Jundishapur J Microbiol 2014; 7(10): e13583. [PubMed]
9. Feltman H, Schulert G, Khan S, et al. Prevalence of type lll secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa. Microbiol 2001; 147(Pt 10): 2659-2669. [PubMed]
10. Clinical and Laboratory Standards Institute (CLSI). (2011) Performance Standards for Antimicrobial Susceptibility Testing. 21th Information Supplement. M100-S21. CLSI, Wayne, PA.
11. Gawish AA, Mohammed NA, El-Shennawy GA, Mohammed HA. An investigation of type 3 secretion toxins encoding-genes of Pseudomonas aeruginosa isolates in a University Hospital in Egypt. Journal of Microbiology and Infectious Diseases. 2013; 3(3): 116-122. [Article]
12. Saleh RH, Naher HS, Al-Saadi MAK. Molecular Investigation of Type III Secretion System Toxins-Encoding Genes in Clinical Isolates of Pseudomonas aeruginosa. Med J Babylon 2012; 9(4): 857-866. [Article]
13. Azimi S, Samadi Kafil H, Bannazadeh Baghi H, Shokrian S, Najaf K, Asgharzadeh M, et al. Presence of exoY, exoS, exoU and exoT genes, antibiotic resistance and biofilm production among Pseudomonas aeruginosa isolates in Northwest Iran. GMS Hyg Infect Control 2016; 11: Doc04. [PubMed]
14. Aghamiri S, Amirmozafari N, FallahMehrabadi J, Fouladtan B, Samadi Kafil H. Antibiotic Resistance Pattern and Evaluation of Metallo-Beta Lactamase Genes Including bla-IMP and bla-VIM Types in Pseudomonas aeruginosa Isolated from Patients in Tehran Hospitals. ISRN Microbiol 2014, Article ID 941507, 6 pages. [Article]
15. Ahmadi K, Hashemian AM, Pouryaghobi SM, Akhavan R, Rozmina S, Bolvardi E. Antibiotic Resistance Properties of Pseudomonas aeruginosa Isolated From Cases of Superficial Infections at the Emergency Unit. Jundishapur J Microbiol 2016; 9(1): e27646. [in Persian] [PubMed]
16. Finlayson EA, Brown PD. Comparison of antibiotic resistance and virulence factors in pigmented and non-pigmented Pseudomonas aeruginosa. West Indian Med J 2011; 60(1): 24-32. [PubMed]
17. Winstanley C, Kaye SB, Neal TJ, Chilton H J, Miksch S, Anthony HC, et al. Genotypic and phenotypic characteristics of Pseudomonas aeruginosa isolates associated with ulcerative keratitis. J Med Microbiol 2005; 54(Pt 6): 519-526. [PubMed]
18. Aghaei SS, Javadi Ali, Sharifi Y, Morovvati A. Detection of Exotoxin A, Y, T, U, S genes of Pseudomonas aeruginosa Isolates Resistant to Third-Generation Cephalosporins in Clinical Samples of Hospitalized Patients in Hospitals of Qom City, Iran. Qom University of Medical Sciences Journal 2016; 10)1(: 48-55. [in Persian] [Article]
19. Khoramrooz SS, Rahbari N, Parhizgari N, Sharifi A, Yazdanpanah M, Gharibpour F, Rabani SM. Frequency of type III Secretion System Cytotoxins -Encoding Genes among Pseudomonas Aeruginosa Isolated from Burn Patients. Journal of Zanjan University of Medical Sciences and Health Services 2015; 23(99): 52-63. [in Persian]
20. Fleiszig SMJ,Wiener-Kronish JP, Miyazaki H,Vallas V, Mostov K, Kanada D, et al. Pseudomonas aeruginosa-mediated cytotoxicity and invasion correlate with distinct genotypes at the loci encoding exoenzyme S. Infect Immun 1997; 65(2): 579-586. [PubMed]
21. Roy-Burman A, Savel RH, Racine S, Swanson BL, Revadigar NS, Fujimoto J, et al. Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J Infect Dis 2001; 183 (12): 1767–1774. [PubMed]
22. Hauser A. The type III secretion system of Pseudomonas aeru‌ginosa: infection by injection. Nat Rev Microbiol 2009; 7(9): 654- 665. [PubMed]
23. Bradbury RS, Roddam LF, Merritt A, et al. Virulence gene dis‌tribution in clinical, nosocomial and environmental isolates of Pseudomonas aeruginosa. J Med Microbiol 2010; 59(8): 881- 890. [PubMed]
24. Wong-Beringer R, Wiener-Kronish J, Lynch S, Flana-gan J. Comparison of type III secretion system virulence among fluoroquinolon-susceptible and –resistant clinical isolates of Pseudomonas aeruginosa. Clin Microbiol Infect 2008; 14(4): 330-336. [PubMed]
25. Sawa T, Shimizu M, Moriyama K, P Wiener-Kronish J. Association between Pseudomonas aeruginosa type III secretion, antibiotic resistance, and clinical outcome: a review. Crit Care 2014; 18(6): 668. [PubMed]
26. Lomholt JA, Poulson K, Kilian M. Epidemic population structure of Pseudomonas aeruginosa: evidence for a clone that is pathogenic to the eye and that has a distinct combination of virulence factors. Infect Immun 2001; 69(10): 6284-6295. [PubMed]
27. Berthelot P, Attree I, Plesiat P, Chabert J, de Bentzmann S, Pozzetto B, et al. phenotypic analysisof type III secretion system in a cohort of Pseudomonas aeruginosa bacteremia isolates: evidence for a possible association between O serotypes and exo genes. J Infect Dis 2003; 188(4): 512–518.
28. Mitov I, Strateva T, Markova B. Prevalence of virulence genes among Bulgarian nosocomial and cystic fibrosis isolates of Pseudomonas aeruginosa. Brazilian J Microbiol 2010; 41(3):588–595. [PubMed]
29. Garey KW, Vo QP, Larocco MT, Gentry LO, Tam VH. Prevalence of type III secretion protein exoenzymes and antimicrobial susceptibility patterns from bloodstream isolates of patients with Pseudomonas aeruginosa bacteremia. J Chemother 2008; 20(6): 714–720. [PubMed]

Add your comments about this article : Your username or Email:

Send email to the article author

© 2020 All Rights Reserved | Iranian Journal of Medical Microbiology

Designed & Developed by : Yektaweb | Publisher: Farname Inc